Poster Presentations

Novel expression systems and innovative platforms

1. **Tyrosinase-mediated bioconjugation of antigens to ferritin nanoparticles**
   Margarida Queluz Rodrigues, Instituto de Biologia Experimental e Tecnológica, Instituto de Tecnologia Química e Biológica, Portugal

2. **Multifactorial high-throughput process screening for a yellow fever virus-vectored Zika vaccine candidate**
   Sven Göbel, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

3. **Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice**
   Eduard Puente-Massaguer, Icahn School of Medicine at Mount Sinai, USA

4. **A scalable, serum-free cell culture platform for improved production of diverse live virus and viral vector vaccine candidates**
   James Wagner, MSD, USA

5. **Influenza A defective interfering particles as broad-spectrum antivirals**
   Sascha Young Kupke, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

6. **C1 gene expression platform rapid, high yield and lower cost way to develop & manufacture biologics**
   Mark Emalfarb, Dyadic International Inc., USA

7. **Enabling commercial process oriented clone selection for a pipeline vaccine candidate through process scale down and analytical characterization**
   Matthew Woodling, Merck & Co, Inc USA, USA

8. **Developing vaccines for common respiratory viruses using a platform technology**
   Andrew Young, University of Queensland, Australia

9. **Enhancing NA immunogenicity through novel VLP designs**
   Leticia Guzmán-Ruiz, University of Natural Resources and Life Sciences, Vienna, Austria

10. **Development of a rapid, cost-effective bioprocess for the production of recombinant human serum albumin in Pichia Pastoris**
    Wanqin Soh, Hilleman Laboratories, Singapore

11. **Development of the Thermophilic Filamentous Fungus Thermothelomyces heterothallica C1 into a prominent human and animal vaccines production platform**
    Mark Emalfarb, Dyadic International Inc., USA

12. **Production of AAV virus-like particles in CHO cells for bioorthogonal chemistry applications**
    Daniel Barreto-Cabrera, Instituto de Biotecnología - Universidad Nacional Autónoma de México, Mexico

13. **Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system**
    Jorge Armero Gimenez, Wageningen University, LenioBio, Germany

14. **Oral administration of a recombinant RBD like from SARS-CoV-2, as immunostimulant for the care of COVID-19**
    Norma Adriana Valdez-Cruz, UNAM, Mexico

15. **FinaXpress, an E. Coli platform for the expression of disulfide-bonded proteins - production of low-cost carrier proteins, vaccine antigens, and biotherapeutics**
    Renaud Jacquemart, Fina Biosolutions, USA

16. TITLE
    TBA

Nucleic acid-based vaccines

17. **Self-amplifying mRNAs encoding chimeric or mosaic influenza virus hemagglutinin antigens induce broadly protective antibody responses in mice**
    Juan Manuel Carreno Quiroz, Icahn School of Medicine at Mount Sinai, USA

18. **Engineering protein nanocompartments for a novel mRNA loading and delivery system**
    Ferdinando Sereno, University College London, United Kingdom

19. **Efficient supply of high quality lineralised pDNA for mRNA production**
    Salomé A. de Sá Magalhães, University College London, United Kingdom

20. **Optimizing in-vitro transcription parameters for production of messenger RNA (mRNA) vaccines**
    Julia Puppin Chaves Fulber, McGill University, Canada

21. **A Phase i, randomized, double-blind, placebo-controlled trial of a Reprna-based vaccine for Covid-19: A brief analysis of safety in adults**
    Bruna Machado, SENAI CIMATEC, Brazil

22. **Development of Rna Vaccines for leishmaniasis and comparison with vaccines based on recombinant antigens**
    Gabriela de Asis Burle-Caldas, UFMG/CTVacinas, Brazil

23. **Univercells develops breakthrough technologies and services that democratize the production of biologics: The potential of Drug Development collaboration**
    David Honba, Univercells, Belgium

24. **Development of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine: Differential effects when co-formulated with Toll Receptor Agonists**
    Allan Watkinson, Labcorp, United Kingdom

25. **A novel genetic vaccine platform using tag/catcher conjugation for modular assembly and secretion of antigen-displaying capsid virus-like particles**
    Cyrielle Fougeroux, Adaptvac, Denmark

26. TITLE
    TBA

Regional development and manufacturing of vaccine

27. **Process development for high titer production of RCA free adenovirus in suspension complementing cell culture derived from A549 cell line**
    Chun Fang Shen, National Research Council of Canada, Canada

28. **Immunogenicity of a trivalent recombinant antigen based on SARS-CoV-2 receptor-binding domain and its variants of concern**
Berenice Calderón-Pérez, CINVESTAV-IPN, Mexico

29. **Development of a vaccine candidate against Clostridium botulinum in cattle**
Berenice Calderón-Pérez, CINVESTAV-IPN, Mexico

30. **Acheviements of a vaccine development unit within Lmics; Biotechnology development unit, Institut Pasteur de Tunis, Tunisia**
samia rourou, Institut Pasteur de Tunis, Tunisia

31. **Upstream development for a Zika Virus Chimeric vaccine**
Tiago Pereira dos Santos, Bio-Manguinhos/FIOCRUZ-RJ, Brazil

32. **Recombinant interleukins as vaccine adjuvants against livestock diseases**
Berenice Calderón-Pérez, CINVESTAV-IPN, Mexico

33. WITHRAWN

34. **Manufacture of a SARS-CoV2 vaccine in Mexico**
Néstor O. Pérez, Probiomed SA de CV, Mexico

35. **Validation of a serological ELISA method to detect anti-SarsCov2 IgG and IgM antibodies in Mexican population.**
Mabel Rodriguez, Instituto de Biotecnología, Mexico

Vaccine manufacturing

36. **Modeling the benefits of small molecule Viral Sensitizers (VSEsTM) to increase virus production**
Jean-Simon Diallo, Virica Biotech, Canada

37. **Disruptive Vibro® technology offering new opportunities in vaccine manufacturing processes**
Jarno Robin, SANI Membranes, Denmark

38. **Intensification of virus production in suspension cells: Comparison of perfusion and fed batch-based processes for different cell lines**
Cristina Silva, Polytechnique Montréal, Canada

39. **The production and purification of an intermediate product for large scale VLP production in insect cells - baculovirus working stock**
Lena Achleitner, acib - Austrian Centre of Industrial Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria

40. **Fixed-bed bioreactor production of virus for vaccine manufacturing**
Renato Astray, Instituto Butantan, Brazil

41. **Sterile purification of large viruses using functionalized non-woven fibers**
Patricia Pereira Aguilar, acib - Austrian Centre of Industrial Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria

42. **Influenza A virus production following quality by design principles**
Tilia Zinnecker, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

43. **Development of next generation manufacturing platform technology for the production of viral vectored vaccines**
Wanqin Soh, Hilleman Laboratories Singapore Pte Ltd, Singapore

44. **Evaluation of a universal influenza B vaccine based on the mosaic hemagglutinin strategy using different vaccine platforms in mice**
Irene González-Domínguez, Icahn School of Medicine at Mount Sinai, USA

45. **Development of a trivalent adjuvanted sub-unit vaccine candidate for Covid-19: From antigen expression to Ind-enabling Cmc and preclinical studies**
Leda R. Castilho, UFRJ, Brazil

46. **Modeling the benefits of small molecule Viral Sensitizers (VSEsTM) to increase virus production**
Jean-Simon Diallo, Virica Biotech, Canada

47. **Bioprocess improvement to increase manufacturing yield using a fixed-bed bioreactor**
Pei-Yin Lim, Hilleman Laboratories, Singapore

48. **Purification platform for poxviruses by filtration processes**
Michael Wolff, University of Applied Sciences Mittelhessen, Germany

49. **The development of a Hi5-Cas9 stable cell line for assessing the impact of AcMNPV essential gene disruption on baculovirus & recombinant protein production using CRISPR-Cas9 technology**
Jacqueline Powichrowski, University of Waterloo, Canada

50. **Impact of animal origin free peptones on HEK293 and vero based vaccine applications**
Ashwin Gurunathan, Thermo Fisher Scientific, USA

51. **Influenza virus capture using membrane chromatography: Improving selectivity by matrix design and pseudo-affinity ligand interactions**
David Dauer, Sartorius Stedim Biotech GmbH, Germany

Analytical technology

52. **Rapid multiplexed analytics for mRNA vaccines**
Erica Dawson, InDevR, Inc., USA

53. **Extraction of intact proteins from polyacrylamide gels for virus-like particle purity reversed-phase HPLC method development**
Jonathan Welsford, MSD, USA

54. **Asymmetric flow field flow fractionation as an analytical tool for virus-like particles**
Narges Lali, ACIB GmbH, BOKU, Austria

55. **Quality assessment of virus-like particle: A new transmission electron microscopy approach**
Salomé A. de Sá Magalhães, University College London, United Kingdom

56. **Application of multivariate data analysis on multi-sensor system for in-line process monitoring of adenovirus production in HEK293 cells**
Xingge Xu, McGill University, Canada

57. **Redox potential of intercapsomeric disulfides defines pathway of final VLP assembly for HPV**

Danielle Miller, Merck, USA

Formulation and stability

58. **Opportunities for process analytical technology integration in the QbD framework for vaccine formulation development and manufacturing**
Nausheen Rahman, sanofi, Canada

59. **Addressing vaccine stability and cold chain challenges with recombinant human serum albumin to enable global administration**
Mark Stathos, InVitria Inc, USA

60. **Bioprocess studies for the production of bacterial vesicles for the delivery of immunogens in epithelial cells**
Mauricio A. Trujillo-Roldán, UNAM, Mexico

61. **Formulation development and characterization of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine with CpG oligonucleotide**
Allan Watkinson, Labcorp, United Kingdom

62. **Formulation development and characterization of a Marburg self-amplifying mRNA-lipid nanoparticle vaccine with a Toll-like receptor 7 agonist**
Allan Watkinson, Labcorp, United Kingdom

63. **Development of a spray dried respiratory tuberculosis vaccine candidate and dosing protocol for a non-human primate study**
John Chen, Access to Advanced Health Institute, USA

64. **Oral COVID-19 vaccination with QYNDR-RBD is safe and immunogenic**
Garry Morefield, VaxForm, USA

Devices and delivery

65. **Lateral flow devices: Applying antigen-antibody interaction for vaccine technology**
Marco Rito-Palomares, Tecnologico de Monterrey, Mexico

One-health

66. **Designing and developing novel peptide inhibitors targeting SARS-CoV-2 entry into host cells using Moroccan scorpion venom molecule mimics**
Naoual OUKKACHE, Institut Pasteur of Morocco, Morocco

67. **High cell density semi-perfusion of CCX.E10 quail cells for production of vesicular stomatitis virus based oncolytic vaccine**
Lennart Jacobtorweihe, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

68. **Bivalent virus-like particles for Circovirus protection and immunocastration**
Diego Fontana, Universidad Nacional Del Litoral, Argentina

69. **Developing anti-helminth vaccines for people and cattle (for)seeing the One Health approach in action**
Renaud Jacquemart, FABP Biotech, Brazil

70. **Click chemistry functionalization of HIV-1-based virus-like particles and extracellular vesicles**
Francesc Gòdia, Universitat Autònoma de Barcelona, Spain